• 1
    Levy RH, Mather GG. Metabolic enzymes and antiepileptic drug interactions. In: French J, Leppik I, Dichter MA, eds. Antiepileptic drug development: advances in neurology. Vol 76. Philadelphia: Lippincott-Raven, 1998:49–55.
  • 2
    Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:117.
  • 3
    Back DJ, Bates M, Bowden A, et al. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 1980;22:495503.
  • 4
    Haukkamaa M. Contraception by Norplant® subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment. Contraception 1986;33:55965.
  • 5
    Odlind V, Olsson S-E. Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with Norplant® implants. Contraception 1986;33:25761.
  • 6
    Crawford P, Chadwick DJ, Martin C, et al. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990;30;892–6
  • 7
    Shane-McWhorter L, Cerveny JD, MacFarlane LL, et al. Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy. Pharmacol Ther 1998;18:13604.
  • 8
    Klosterskov Jensen P, Saano V, et al. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992;33:114952.
  • 9
    Saano V, Glue P, Banfield CR, et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin Pharmacol Ther 1995;58:52331.
  • 10
    Rosenfeld WE, Doose DR, Walker SA, et al. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997;38:31723.
  • 11
    Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999;40:7837.
  • 12
    Gatti G, Bonomi I, Jannuzzi G, et al. The new antiepileptic drugs: pharmacological and clinical aspects. Curr Pharm Design 2000;6:83960.
  • 13
    McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology 1994;44(suppl 5):S1722.
  • 14
    Strolin Benedetti M. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fund Clin Pharmacol 2000;14:30119.
  • 15
    Bartoli A, Gatti G, Cipolla G, et al. A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. Epilepsia 1997;38:7027.
  • 16
    Eldon MA, Underwood BA, Randinitis EJ, et al. Gabapentin does not interact with a contraceptive regimen of norethindrone acetate and ethinyl estradiol. Neurology 1998;50:11468.
  • 17
    Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000;85:7785.
  • 18
    Nicolas J-M, Collart P, Gerin B, et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos 1999;27:2504.
  • 19
    Shorvon SD, Löwenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000;41:117986.
  • 20
    Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:23642.
  • 21
    Browne TR, Szabo GK, Leppik IE, et al. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. J Clin Pharmacol 2000;40:5905.
  • 22
    Kuhnz W, Heuner A, Humpel M, et al. In vivo conversion of norethisterone and norethisterone acetate to ethinyl estradiol in postmenopausal women. Contraception 1997;56:37985.DOI: 10.1016/S0010-7824(97)00174-1
  • 23
    Häring N, Baumeister A, Salama ZB, et al. Determination of the progestins levonorgestestrel and norethindrone in human plasma by GC/MS. Sci Pharm 1994;62:1323.
  • 24
    Steinijans VW, Hartmann M, Huber R, et al. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 1991;29:3238.
  • 25
    Thomas L, ed. Labor und Diagnose. Indikation und Bewertung von Laborefunden für die Medizinische Diagnostik. ed 3. Marburg, Germany: Die Medizinische Verlags-gesellschaft, 1988.
  • 26
    Teichmann AT. Kontrazeption. Ein Kompendium für Klinik und Praxis. Gynäkologie und Geburtsmedizin, 4th ed. Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft, 1991.
  • 27
    Chang S-I, McAuley JW. Pharmacotherapeutic issues for women of childbearing age with epilepsy. Ann Pharmacother 1998;32:794801.
  • 28
    Wilbur K, Ensom MHH. Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants. Clin Pharmacokinet 2000;38:35565.
  • 29
    Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 1996;42:53143.
  • 30
    Crawford P, Chadwick D, Cleland P, et al. The lack of effect of sodium Valproate on the pharmacokinetics of oral contraceptive steroids. Contraception 1986;33:239.
  • 31
    Holdich T, Whiteman P, Orme M, et al. Effect of lamotrigine on the pharmacology of the combined oral contraceptive pill. Epilepsia 1991; 32(suppl 1):96.
  • 32
    Mengel HB, Houston A, Back DJ. An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers. J Pharm Med 1994;4:14150.